Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07328971 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Vancomycin Taper to Prevent Recurrent Clostridioides Difficile

Study acronym: TAPER-V2
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Lead sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre to McGill University Health Centre/Research Institute of the McGill University Health Centre Show 4 more changesShow less
    • Study sites: 1 to 2
    • Eligibility criteria expanded, about 15 words
    • Study description revised
    • Publications: details revised at 3 of 3 entries
  2. Eligibility criteria shortened, about 9 wordsv3
  3. Recruitment opened
    • Start date changed from estimate of Jun 1, 2026 to Apr 24, 2026
    • Site details revised
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Indirect evidence from network meta-analyses of randomized controlled trials (RCTs) suggest that a pulse and taper (P-T) of vancomycin may be non-inferior to 10-days of fidaxomicin for the prevention of recurrent Clostridioides difficile infections (rCDI). The aim of this trial is: 1\) For first episodes and first recurrences of CDI, to test whether a vancomycin P-T is non-inferior to 10-days of fidaxomicin for the prevention of rCDI at 56 days
Trial Details
NCT Number NCT07328971
Lead Sponsor McGill University Health Centre/Research Institute of the McGill University Health Centre
Conditions
(from sponsor)		 Clostridia Difficile Colitis
Related terms Enterocolitis, Pseudomembranous
Enrollment 500 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov